Technical Analysis for PTCT - PTC Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Doji - Bullish? | Reversal | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Wide Bands | Range Expansion | -2.04% | |
| Down 3 Days in a Row | Weakness | -2.04% | |
| Down 4 Days in a Row | Weakness | -2.04% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -5.52% |
| Alert | Time |
|---|---|
| Down 3% | about 13 hours ago |
| 60 Minute Opening Range Breakdown | about 13 hours ago |
| 10 DMA Resistance | about 15 hours ago |
| Fell Below Previous Day's Low | about 16 hours ago |
| Down 2 % | about 16 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/16/2024
PTC Therapeutics, Inc. Description
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules. The company has strategic alliances with AstraZeneca; Celgene Corporation; Cystic Fibrosis Foundation; Genzyme Corporation; Gilead; Muscular Dystrophy Association; Merck & Co., Inc.; Parent Project Muscular Dystrophy; Pfizer Inc.; Roche; Spinal Muscular Atrophy Foundation; and Wellcome Trust. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Infectious Diseases Neurological Disorders Dystrophy Gene Expression Muscular Dystrophy Cystic Fibrosis Neurodegenerative Disorders Transcription Spinal Muscular Atrophy Genzyme Neuromuscular Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 59.75 |
| 52 Week Low | 17.53 |
| Average Volume | 908,762 |
| 200-Day Moving Average | 28.42 |
| 50-Day Moving Average | 29.05 |
| 20-Day Moving Average | 28.58 |
| 10-Day Moving Average | 31.50 |
| Average True Range | 1.69 |
| RSI (14) | 57.45 |
| ADX | 30.65 |
| +DI | 29.76 |
| -DI | 19.75 |
| Chandelier Exit (Long, 3 ATRs) | 30.41 |
| Chandelier Exit (Short, 3 ATRs) | 29.06 |
| Upper Bollinger Bands | 35.48 |
| Lower Bollinger Band | 21.68 |
| Percent B (%b) | 0.69 |
| BandWidth | 48.30 |
| MACD Line | 1.32 |
| MACD Signal Line | 0.82 |
| MACD Histogram | 0.504 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 32.48 | ||||
| Resistance 3 (R3) | 32.49 | 32.04 | 32.26 | ||
| Resistance 2 (R2) | 32.04 | 31.70 | 32.04 | 32.18 | |
| Resistance 1 (R1) | 31.59 | 31.49 | 31.82 | 31.59 | 32.11 |
| Pivot Point | 31.15 | 31.15 | 31.26 | 31.15 | 31.15 |
| Support 1 (S1) | 30.70 | 30.81 | 30.92 | 30.69 | 30.17 |
| Support 2 (S2) | 30.25 | 30.60 | 30.25 | 30.10 | |
| Support 3 (S3) | 29.80 | 30.25 | 30.02 | ||
| Support 4 (S4) | 29.80 |
